Streetbeat News

Stock Prices

HUM

NKE

TGL

Humana shares dropped 25% due to a decline in Stars performance affecting future quality bonus payments. Nike shares fell 8% after missing Q1 revenue estimates. Treasure Global shares surged 74% following the completion of its equity offering program.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:23 pm

VCYT

Veracyte, Inc. presented new data from the VANDAAM trial at ASTRO 2024, showing that its Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer in African American men. This test offers an improvement over clinical factors alone in guiding treatment decisions for this disproportionately affected population.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:23 pm

HUM

NKE

TRP

Nike reported weak first-quarter sales, missing revenue estimates but beating earnings expectations. This led to a 5.5% decline in pre-market trading. Other stocks like Humana, TC Energy, and Lamb Weston also saw declines due to various company-specific news.

Portfolio Pulse from Avi Kapoor

October 02, 2024 | 12:21 pm

ATYR

aTyr Pharma announced the publication of a study in the European Respiratory Journal showing the efficacy of efzofitimod in treating pulmonary sarcoidosis. The study demonstrated a significant reduction in relapse rates for patients on therapeutic doses compared to subtherapeutic doses.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:15 pm

SPY

The USA ADP Nonfarm Employment Change for September was reported at 143K, surpassing the estimated 124K and the prior month's 103K. This indicates a stronger-than-expected job growth in the private sector.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:15 pm

ESPR

Esperion's European partner, Daiichi Sankyo Europe, reported positive real-world results from the MILOS study in Germany, showing significant LDL-C reduction with bempedoic acid. The study demonstrated a 7-fold increase in patients achieving LDL-C goals, confirming the drug's effectiveness and safety.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:15 pm

BNTX

GOOG

GOOGL

Google DeepMind, part of Alphabet Inc., and BioNTech are collaborating to develop AI lab assistants to enhance scientific research. This partnership aims to revolutionize research by using AI to facilitate interdisciplinary collaboration and automate routine tasks, potentially boosting productivity and aiding in cancer treatment research.

Portfolio Pulse from Benzinga Neuro

October 02, 2024 | 12:11 pm

MGNI

SSTK

The article highlights three oversold stocks in the communication services sector: Magnite Inc (MGNI), Shutterstock Inc (SSTK), and Eventbrite Inc (EB). These stocks have RSI values near or below 30, indicating potential undervaluation. Analyst Laura Martin reiterated a Buy rating for Magnite with a $15 price target. Shutterstock announced a leadership change, and Eventbrite engaged in repurchase transactions for its convertible notes.

Portfolio Pulse from Avi Kapoor

October 02, 2024 | 12:09 pm

URGN

UroGen Pharma has dosed the first patient in a Phase 3 trial for UGN-103, targeting low-grade intermediate-risk non-muscle invasive bladder cancer. The trial features an improved manufacturing and reconstitution process.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:07 pm

ALUR

KXIN

NKE

PIK

QSG

VEEE

In Wednesday's pre-market session, several consumer discretionary stocks experienced significant movements. Kaixin Holdings (KXIN) saw an 80.2% increase, while Nike (NKE) fell by 7.7% following its Q1 earnings report. Other notable gainers include QuantaSing Group (QSG) and Allurion Technologies (ALUR), while Kidpik (PIK) and Twin Vee PowerCats (VEEE) were among the losers.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 12:06 pm